DOCSLIB.ORG

Urine and Serum S100A8/A9 and S100A12 Associate with Active Lupus Nephritis and May Predict Response to Rituximab Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Urine and Serum S100A8/A9 and S100A12 Associate with Active Lupus Nephritis and May Predict Response to Rituximab Treatment Lupus RMD Open: first published as 10.1136/rmdopen-2020-001257 on 28 July 2020. Downloaded from Original research Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment Jennifer C Davies,1 Angela Midgley,1 Emil Carlsson,1 Sean Donohue,1 Ian N Bruce,2 Michael W Beresford,1,3 Christian M Hedrich 1,3 To cite: Davies JC, Midgley A, ABSTRACT et al Key messages Carlsson E, . Urine and Background Approximately 30% of patients with the serum S100A8/A9 and S100A12 systemic autoimmune/inflammatory disorder systemic lupus associate with active lupus What is already known about this subject? erythematosus (SLE) develop lupus nephritis (LN) that affects nephritis and may predict ► Though ≈30% of patients with Systemic lupus treatment and prognosis. Easily accessible biomarkers do not response to rituximab treatment. erythematosus (SLE) develop lupus nephritis that exist to reliably predict renal disease. The Maximizing SLE RMD Open 2020;6:e001257. affects treatment and prognosis, easily accessible Therapeutic Potential by Application of Novel and Systemic doi:10.1136/rmdopen-2020- biomarkers do not exist to reliably predict renal Approaches and the Engineering Consortium aims to identify 001257 disease. indicators of treatment responses in SLE. This study tested ► Supplemental material is the applicability of calcium-binding S100 proteins in serum published online only. To view What does this study add? ► please visit the journal online and urine as biomarkers for disease activity and response to Serum S100A12, and serum and urine S100A8/A9 (http://dx.doi.org/10.1136/rmdo treatment with rituximab (RTX) in LN. (p<0.001) levels are elevated in SLE patients, and pen-2020-001257). Methods S100A8/A9 and S100A12 proteins were levels in urine and urine/serum ratios are elevated in quantified in the serum and urine of 243 patients with SLE patients with active LN. MWB and CH contributed from the British Isles Lupus Assessment Group Biologics ► Binary logistic regression and AUC analyses equally. Register (BILAG-BR) study and 48 controls matched for age suggests the combination of serum S100A8/A9 and ’ http://rmdopen.bmj.com/ Received 1 April 2020 using Meso Scale Discovery s technology to determine S100A12 can predict response to RTX treatment in Revised 27 May 2020 whether they perform as biomarkers for active LN and/or LN after 6 months. Accepted 7 June 2020 may be used to predict response to treatment with RTX. Renal disease activity and response to treatment was based How might this impact on clinical practice? on BILAG-BR scores and changes in response to treatment. ► While findings show promise for clinical application Results Serum S100A12 (p<0.001), and serum and urine of S100 proteins to predict active LN and response to S100A8/A9 (p<0.001) levels are elevated in patients with treatment with rituximab, they require to be SLE. While serum and urine S100 levels do not correlate confirmed in independent cohorts and longitudinal/ with global disease activity (SLE Disease Activity Index), prospective studies. levels in urine and urine/serum ratios are elevated in on September 30, 2021 by guest. Protected copyright. patients with active LN. S100 proteins perform better as biomarkers for active LN involvement in patients with SLE interactions of genetic factors, the environ- who tested positive for anti-double-stranded DNA ment and hormones contribute to disease 12 antibodies. Binary logistic regression and area under the expression. Tissue inflammation and organ curve analyses suggest the combination of serum S100A8/ damage are caused by immune cell dysregula- A9 and S100A12 can predict response to RTX treatment in tion including enhanced generation and acti- LN after 6 months. vation of effector T cells, altered cytokine Conclusions Findings from this study show promise for expression, B cell activation, autoantibody pro- clinical application of S100 proteins to predict active renal duction, immune complex deposition and disease in SLE and response to treatment with RTX. 34 © Author(s) (or their complement activation. employer(s)) 2020. Re-use Approximately 30% of adult-onset patients – permitted under CC BY. with SLE develop renal disease,5 7 and damage Published by BMJ. INTRODUCTION is strongly associated with morbidity and For numbered affiliations see Systemic lupus erythematosus (SLE) is mortality.89Diagnosing renal disease and mea- end of article. a systemic autoimmune/inflammatory disease suring its activity can be challenging, especially Correspondence to that can affect any organ of the human body. since frequently tested nephritis-associated pro- Christian Hedrich; christian. The molecular pathophysiology of SLE teinuria cannot reliably predict WHO nephritis [email protected] remains largely unknown, but complex class (that centrally influences treatment Davies JC, et al. RMD Open 2020;6:e001257. doi:10.1136/rmdopen-2020-001257 1 RMD Open RMD Open: first published as 10.1136/rmdopen-2020-001257 on 28 July 2020. Downloaded from decision) and/or inflammatory activity (since damage can PATIENTS AND METHODS result in renal protein loss). Thus, currently, renal biopsies Patients are used to reliably determine renal disease and/or the Serum and urine samples were collected from adult- form (WHO class) and extent of renal disease.10 onset patients with SLE (n=243) in the UK through Patients with SLE exhibit extraordinarily variable centres involved in the British Isles Lupus Assessment treatment responses, and we are currently unable to Group (BILAG) Biologics Register (BR). The BILAG- predict response to treatment options available. BR received ethical approval from the Health Research Though treatment recommendations for patients Authority dated 9 November 2009 (IRAS ref. 24407) with SLE-associated renal disease have been and written informed consent was obtained in accor- published,11 12 not all patients will respond to first- dance with the declaration of Helsinki. Serum (n=236) line agents and treatment optimisation not uncom- and urine (n=199) samples were collected at baseline in monly follows trial-and-error strategies. Thus, the patients who were being initiated on a change in immu- identification of pathomechanisms involved and the nosuppressive/immunomodulatory treatment. Samples establishment of predictive biomarkers are urgently were sent at ambient temperature in the overnight post needed to optimise treatment. Indeed, biologically for processing at a central laboratory at the Centre for informed individualised and target-directed Musculoskeletal Research, University of Manchester. approaches promise to be of benefit to both patients Clinical details including demographic data, concur- and healthcare systems by reducing disease burden, rent treatment, disease activity and treatment response time to remission, disease-associated damage and dis- were obtained from medical records through BILAG- ability, and treatment-associated cost.13 Depletion of BR. Patients were excluded from analysis if they were B lymphocytes with rituximab (RTX) can reduce SLE taking other biologic disease-modifying anti-rheumatic disease activity in a subset of patients with SLE, but drugs, and background doses of immunosuppressive only half of patients with SLE respond to RTX after drugs and corticosteroid were determined by the local 6months.14 15 However, biomarkers to predict treat- treating physician according to their usual clinical prac- ment responses and/or disease outcomes are currently tice ‘low-dose’ corticosteroids (table 1). All patients not available. included met the 1997 American College of Rheuma- Calcium-binding S100 proteins are mainly expressed tology classification criteria for SLE.23 Furthermore, in granulocytes and mononuclear blood cells such as serum and urine samples were obtained from 48 adult neutrophils and macrophages.16 17 More recently, healthy donors as controls (HC). Individual data points expression of these S100 proteins has been reported that required to be excluded from analysis are sum- in renal endothelial cells.18 Elevated serum concentra- marised in online supplementary table 1. tions of S100 proteins have been linked with systemic http://rmdopen.bmj.com/ inflammatory conditions in children and adults.19 Classification of disease activity Recently, elevated levels of pro-inflammatory The BILAG-2004 grade system scores disease activity as S100A12 and heterodimeric S100A8/A9 in serum follows: A (severe disease), B (moderate disease), and urine samples from patients with juvenile-onset C (mild or improving disease), D (inactive disease but SLE and in serum of adult-onset patients with SLE previous system disease) and E (system has never been – 24 were reported to correlate with renal disease.20 22 Pre- involved). For data interpretation, active disease of vious studies have not examined S100 proteins in the any system was defined as having grade A or B and inactive disease as D or E. Scores of C were not included serum and urine from the same patients and did not on September 30, 2021 by guest. Protected copyright. address the potential of combining S100 protein levels in the analysis to provide distinct disease states. To from serum and urine to determine systemic and/or generate global BILAG-BR scores, letters A, B, C, renal disease status. Furthermore, the predictive value D and E for each nine domains were converted to 25 of S100 expression regarding treatment responses has numerical scores, as previously described, and the not
Load more

Recommended publications
  • Certificate of Analysis – Technical Data Sheet
    CERTIFICATE OF ANALYSIS – TECHNICAL DATA SHEET Product name S100A12, Human, clone 203 Catalog number HM2369 Lot number - Expiry date - Volume 1 ml Amount 100 µg Formulation 0.2 µm filtered in PBS+0.1%BSA+0.02%NaN3 Concentration 100 µg/ml Host Species Mouse IgG2a Conjugate None Endotoxin N.A. Purification Protein G Storage 4°C Application notes IHC-F IHC-P IF FC FS IA IP W Reference # Yes ● ● No N.D. ● ● ● ● ● ● N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot W: Recombinant S100A12 0.25 µg was loaded. The concentration of HM2369 was 2 µg/ml. Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. IA: Antibody clone 2 can be used as capture and detection antibody. W: A reduced sample treatment and SDS-Page was used. The band size is ~11 kDa. General Information Description The monoclonal antibody clone 203 recognizes S100 calcium-binding protein A12 (S100A12). The antibody does not cross-react with family members S100A7, S100A8 and S100A9 and S100A8/A9 heterodimers. S100A12, also known as calgranulin C, is a member of the S100 protein family. To date, the family consists of 22 members. S100 proteins are low molecular weight calcium binding proteins. The proteins consist of 2 calcium binding EF-hands located on the termini flanked by hydrophobic hinge regions.
    [Show full text]
  • Urine S100 Proteins As Potential Biomarkers of Lupus Nephritis Activity Jessica L
    Turnier et al. Arthritis Research & Therapy (2017) 19:242 DOI 10.1186/s13075-017-1444-4 RESEARCHARTICLE Open Access Urine S100 proteins as potential biomarkers of lupus nephritis activity Jessica L. Turnier1*, Ndate Fall1, Sherry Thornton1, David Witte2, Michael R. Bennett3, Simone Appenzeller4, Marisa S. Klein-Gitelman5, Alexei A. Grom1 and Hermine I. Brunner1 Abstract Background: Improved, noninvasive biomarkers are needed to accurately detect lupus nephritis (LN) activity. The purpose of this study was to evaluate five S100 proteins (S100A4, S100A6, S100A8/9, and S100A12) in both serum and urine as potential biomarkers of global and renal system-specific disease activity in childhood-onset systemic lupus erythematosus (cSLE). Methods: In this multicenter study, S100 proteins were measured in the serum and urine of four cSLE cohorts and healthy control subjects using commercial enzyme-linked immunosorbent assays. Patients were divided into cohorts on the basis of biospecimen availability: (1) longitudinal serum, (2) longitudinal urine, (3) cross-sectional serum, and (4) cross-sectional urine. Global and renal disease activity were defined using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and the SLEDAI-2K renal domain score. Nonparametric testing was used for statistical analysis, including the Wilcoxon signed-rank test, Kruskal-Wallis test, Mann-Whitney U test, and Spearman’s rank correlation coefficient. Results: All urine S100 proteins were elevated in patients with active LN compared with patients with active extrarenal disease and healthy control subjects. All urine S100 protein levels decreased with LN improvement, with S100A4 demonstrating the most significant decrease. Urine S100A4 levels were also higher with proliferative LN than with membranous LN.
    [Show full text]
  • Elevated Gene Expression of S100A12 Is Correlated with the Predominant Clinical Inflammatory Factors in Patients with Bacterial Pneumonia
    MOLECULAR MEDICINE REPORTS 11: 4345-4352, 2015 Elevated gene expression of S100A12 is correlated with the predominant clinical inflammatory factors in patients with bacterial pneumonia FEI HOU1*, LIKUI WANG2*, HONG WANG1, JUNCHAO GU3, MEILING LI4, JINGKAI ZHANG4, XIAO LING4, XIAOFANG GAO4 and CHENG LUO4 1Department of Infection, Beijing Friendship Hospital, Capital Medical University, Beijing 100050; 2CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Chaoyang, Beijing 100101; 3Beijing Tropical Medicine Research Institute, Beijing Friendship Hospital, Capital Medical University, Beijing 100050; 4Key Laboratory of Food Nutrition and Safety, School of Food Engineering and Biotechnology, Tianjin University of Science and Technology, Binhai, Tianjin 300457, P.R. China Received March 19, 2014; Accepted December 19, 2014 DOI: 10.3892/mmr.2015.3295 Abstract. Inflammation is the predominant characteristic of S100A12 was observed in a heatmap among the patients with pneumonia. The present study aimed to to identify a faster and different infections and bacterial pneumonia. Furthermore, the more reliable novel inflammatory marker for the diagnosis of expression of S100A12 occurred in parallel to the number of pneumonia. The expression of the S100A12 gene was analyzed clumps of inflamed tissue observed in chest computed tomog- by reverse transcription quantitative polymerase chain reac- raphy and X‑ray. The value of gene expression of S100A12 tion in samples obtained from 46 patients with bacterial (>1.0) determined using the 2‑ΔΔCt method was associated with pneumonia and other infections, compared with samples from more severe respiratory diseases in the patients compromised 20 healthy individuals, using the 2‑ΔΔCt method. The expression by bacterial pneumonia, sepsis and pancreatitis.
    [Show full text]
  • Is Strongly Expressed During Chronic Active Inflammatory Bowel Disease
    847 INFLAMMATORY BOWEL DISEASE Neutrophil derived human S100A12 (EN-RAGE) is Gut: first published as 10.1136/gut.52.6.847 on 1 June 2003. Downloaded from strongly expressed during chronic active inflammatory bowel disease D Foell, T Kucharzik, M Kraft, T Vogl, C Sorg, W Domschke, J Roth ............................................................................................................................. Gut 2003;52:847–853 Background: Intestinal inflammation in Crohn’s disease (CD) and ulcerative colitis (UC) is character- ised by an influx of neutrophils into the intestinal mucosa. S100A12 is a calcium binding protein with proinflammatory properties. It is secreted by activated neutrophils and interacts with the multiligand receptor for advanced glycation end products (RAGE). Promising anti-inflammatory effects of blocking agents for RAGE have been reported in murine models of colitis. Aims: To investigate expression and serum concentrations of S100A12 in inflammatory bowel disease (IBD). Methods: We performed immunohistochemical studies and immunofluorescence microscopy in biop- See end of article for sies from patients with CD and UC. S100A12 serum concentrations were analysed using a sandwich authors’ affiliations ELISA. ....................... Results: Immunohistochemical studies revealed profound expression of S100A12 in inflamed intesti- Correspondence to: nal tissue from IBD patients whereas no expression was found in tissue from healthy controls. Staining Dr D Foell, Institute of for S100A12 during chronic active CD and UC was restricted to infiltrating neutrophils. Serum Experimental Dermatology, S100A12 levels were significantly elevated in patients with active CD (470 (125) ng/ml; p<0.001, University of Münster, Von-Esmarch-Str 58, n=30) as well as those with active UC (400 (120) ng/ml; p<0.01, n=15) compared with healthy con- 48149 Münster, Germany; trols (75 (15) ng/ml; n=30).
    [Show full text]
  • Original Article Expression of S100 Family Proteins in Neonatal Rats with Sepsis and Its Significance
    Int J Clin Exp Pathol 2015;8(2):1631-1639 www.ijcep.com /ISSN:1936-2625/IJCEP0004338 Original Article Expression of S100 family proteins in neonatal rats with sepsis and its significance Haiying Huang, Luoyang Tu Department of Critical Care Medicine, Sir Run Run Shaw Hospital affiliated School of Medicine, Zhejiang Univer- sity, 3 East Qingchun Rd. Jianggan District, Hangzhou, Zhejiang Province, People’s Republic of China Received December 1, 2014; Accepted January 28, 2015; Epub February 1, 2015; Published February 15, 2015 Abstract: Objective: This study aims to study the expression changes of S100 family proteins in neonatal rats with sepsis and investigate the effect and significance of S100 family proteins in pathogenesis and development of sepsis. Methods: The functions of S100 family proteins were analyzed with bioinformatics. The immune-associated proteins were chosen as the candidate proteins. Twenty neonatal SPF SD rats were randomly divided into two groups: sepsis model group and control group. The liver sample was stained with HE to evaluate the establishment of sepsis model. The expression amount of proinflammatory factor IL-1, IL-6 and TNF-α was detected with ELISA. The expression changes of S100A8, S100A9, S100A11 and S100A12 in sepsis model rats were detected with real-time PCR and Western blotting. After shRNA plasmid was transfected into THP-1 cells and the expression of S100A12 was silenced, the expression changes of proinflammatory factor IL-1, IL-6 and TNF-α in LPS-induced inflammation were studied in order to investigate the S100A12 mediated inflammatory process. Results: IL-1, IL-6 and TNF-α in the serum of rats with sepsis induced by LPS were 55.79 ± 3.80 ng/l, 48.76 ± 1.03 ng/l and 29.98 ± 2.27 ng/l respectively.
    [Show full text]
  • A Link Between Inflammation and Metastasis
    Oncogene (2015) 34, 424–435 & 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc ORIGINAL ARTICLE A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4 MT Hansen1,8, B Forst1,8, N Cremers2,3, L Quagliata2, N Ambartsumian1,4, B Grum-Schwensen1, J Klingelho¨ fer1,4, A Abdul-Al1, P Herrmann5, M Osterland5, U Stein5, GH Nielsen6, PE Scherer7, E Lukanidin1, JP Sleeman2,3,9 and M Grigorian1,4,9 S100A4 is implicated in metastasis and chronic inflammation, but its function remains uncertain. Here we establish an S100A4- dependent link between inflammation and metastatic tumor progression. We found that the acute-phase response proteins serum amyloid A (SAA) 1 and SAA3 are transcriptional targets of S100A4 via Toll-like receptor 4 (TLR4)/nuclear factor-kB signaling. SAA proteins stimulated the transcription of RANTES (regulated upon activation normal T-cell expressed and presumably secreted), G-CSF (granulocyte-colony-stimulating factor) and MMP2 (matrix metalloproteinase 2), MMP3, MMP9 and MMP13. We have also shown for the first time that SAA stimulate their own transcription as well as that of proinflammatory S100A8 and S100A9 proteins. Moreover, they strongly enhanced tumor cell adhesion to fibronectin, and stimulated migration and invasion of human and mouse tumor cells. Intravenously injected S100A4 protein induced expression of SAA proteins and cytokines in an organ-specific manner. In a breast cancer animal model, ectopic expression of SAA1 or SAA3 in tumor cells potently promoted widespread metastasis formation accompanied by a massive infiltration of immune cells.
    [Show full text]
  • Phagocyte-Specific S100 Proteins Are Released from Affected Mucosa and Promote Immune Responses During Inflammatory Bowel Diseas
    Journal of Pathology J Pathol 2008; 216: 183–192 Published online 17 June 2008 in Wiley InterScience (www.interscience.wiley.com) DOI: 10.1002/path.2394 Original Paper Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease D Foell,1,2* H Wittkowski,1,2,3 Z Ren,4 J Turton,4 GPang,5 JDaebritz,1,2 J Ehrchen,3 J Heidemann,6 T Borody,7 J Roth1,2,3 and R Clancy4 1Department of Paediatrics, University of Munster,¨ Germany 2Interdisciplinary Centre of Clinical Research, University of Munster,¨ Germany 3Institute of Immunology, University of Munster,¨ Germany 4Hunter Immunology Unit, Hunter New England Area Health Service, John Hunter Hospital, Newcastle, NSW, Australia 5Discipline of Immunology and Microbiology, School of Biomedical Sciences, University of Newcastle, NSW, Australia 6Department of Medicine B, University of Munster,¨ Germany 7Centre for Digestive Diseases, Five Dock, NSW, Australia *Correspondence to: Abstract D Foell, Department of Paediatrics, University of Phagocyte-derived S100 proteins are endogenous activators of innate immune responses. Munster,¨ S100A12 binds to the receptor for advanced glycation end-products, while complexes of Albert-Schweitzer-Strasse 33, S100A8/S100A9 (myeloid-related proteins, MRP8/14; calprotectin) are ligands of toll-like D-48149 Munster,¨ Germany. receptor 4. These S100 proteins can be detected in stool. In the present study we analyse E-mail: [email protected] the release of S100A12 and MRP8/14 from intestinal tissue. Specimens from patients with Crohn’s disease (CD; n = 30), ulcerative colitis (UC; n = 30), irritable bowel syndrome No conflicts of interest were = = declared.
    [Show full text]
  • Helicobacter Pylori Cytotoxin‑Associated Gene a Activates Tumor
    MOLECULAR MEDICINE REPORTS 12: 6337-6345, 2015 Helicobacter pylori cytotoxin‑associated gene A activates tumor necrosis factor‑α and interleukin‑6 in gastric epithelial cells through P300/CBP‑associated factor‑mediated nuclear factor‑κB p65 acetylation QIONG LIN, HUI XU, XINTAO CHEN, GUORONG TANG, LAN GU and YEHONG WANG Department of Gastroenterology, Wuxi Children's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023, P.R. China Received October 19, 2014; Accepted July 2, 2015 DOI: 10.3892/mmr.2015.4143 Abstract. Helicobacter pylori-initiated chronic gastritis Korea being higher than those in developed countries (1‑5). is characterized by the cytotoxin-associated gene (Cag) Helicobacter pylori colonizes the stomach and duodenum pathogenicity island‑dependent upregulation of pro‑inflam- areas, causing chronic inflammation of the gastric mucosa, matory cytokines in gastric epithelial cells, which is largely and the development of stomach ulcers and neoplasms mediated by the activation of nuclear factor (NF)‑κB as a (gastric cancer and mucosa‑associated lymphoid tissue) (6,7). transcription factor. However, the precise regulation of NF‑κB However, the mechanism by which Helicobacter pylori activation, particularly post‑translational modifications in the infection causes pathological changes of the gastric mucosa CagA‑induced inflammatory response, has remained elusive. remains to be fully elucidated. The present study showed that Helicobacter pylori CagA, Inflammatory responses have been known to have a key an important virulence factor, induced the expression of role in the pathogenesis of Helicobacter pylori infection P300/CBP‑associated factor (PCAF) in gastric epithelial cells. and contribute to chronic gastritis as well as gastric and Further study revealed that PCAF was able to physically asso- duodenal ulcers in the patients (8‑10).
    [Show full text]
  • Improving Relapse Prediction in Inflammatory Bowel Disease By
    ORIGINAL ARTICLE Improving Relapse Prediction in Inflammatory Bowel Disease by Neutrophil-Derived S100A12 ,†,‡ § ¶ Jan Däbritz, MD,* Jost Langhorst, MD, Andreas Lügering, MD,k Jan Heidemann, MD, Miriam Mohr, MD,§ Helmut Wittkowski, MD,* Thomas Krummenerl, MD,** and Dirk Foell, MD*,† Background: Prediction of inflammatory bowel disease relapse has important implications for therapeutic strategies. Fecal S100A12 has been reported as a novel marker of intestinal inflammation. The objective was to investigate the utility of S100A12 as a marker for the confirmation of stable remission and prediction of relapses. Methods: We consecutively included 147 adults and 34 children with Crohn’s disease (n 61) or ulcerative colitis (n 120). Over a 3-year period, we ¼ ¼ collected 686 stool samples and 861 serum samples during regular follow-up visits. S100A12 and calprotectin levels were measured by an enzyme-linked immunoassay. Results: Fecal S100A12 correlated with S100A12 serum levels, other laboratory markers, as well as disease activity, location, and behavior. Fecal S100A12 levels in the relapse group differed significantly from those of the nonrelapse group. A baseline fecal S100A12 level of .0.5 mg/kg was significantly associated with disease relapse within 18 months. Time course analysis of fecal S100A12 before and after relapse showed a clear increase of S100A12 concentrations up to 6 months before clinical relapse. At 0.43 mg/kg, the sensitivity and specificity of S100A12 for predicting relapse already 8 to 12 weeks earlier were 70% and 83%, respectively. Conclusions: Regular measurements of fecal S100A12 levels reliably detect inflammatory bowel disease relapse at an early stage, which makes the test a promising noninvasive tool for monitoring and optimizing therapy, and may reduce the need for invasive investigations during disease follow-up.
    [Show full text]
  • High Monocyte Count and Expression of S100A9 and S100A12 In
    cancers Article High Monocyte Count and Expression of S100A9 and S100A12 in Peripheral Blood Mononuclear Cells Are Associated with Poor Outcome in Patients with Metastatic Prostate Cancer Anna-Maja Åberg 1, Sofia Halin Bergström 1, Elin Thysell 1, Lee-Ann Tjon-Kon-Fat 2, Jonas A. Nilsson 2, Anders Widmark 2, Camilla Thellenberg-Karlsson 2 , Anders Bergh 1 , Pernilla Wikström 1 and Marie Lundholm 1,* 1 Department of Medical Biosciences, Pathology, Umeå University, 901 85 Umeå, Sweden; [email protected] (A.-M.Å.); sofi[email protected] (S.H.B.); [email protected] (E.T.); [email protected] (A.B.); [email protected] (P.W.) 2 Department of Radiation Sciences, Oncology, Umeå University, 901 85 Umeå, Sweden; [email protected] (L.-A.T.-K.-F.); [email protected] (J.A.N.); [email protected] (A.W.); [email protected] (C.T.-K.) * Correspondence: [email protected]; Tel.: +46-907854405 Simple Summary: Prostate tumors are heterogeneous with unpredictable outcomes, ranging from harmless to aggressive, metastatic and deadly disease. Current diagnostic methods have limited Citation: Åberg, A.-M.; Bergström, ability to predict disease aggressiveness. New biomarkers are urgently needed to improve risk S.H.; Thysell, E.; Tjon-Kon-Fat, L.-A.; stratification, preferably involving non-invasive procedures. The aim of this prospective study was Nilsson, J.A.; Widmark, A.; to assess the prognostic value of the inflammation markers S100A9 and S100A12 together with the Thellenberg-Karlsson, C.; Bergh, A.; monocyte count in blood samples from a cohort of 121 prostate cancer patients. We show that high Wikström, P.; Lundholm, M.
    [Show full text]
  • S100A12 in Digestive Diseases and Health: a Scoping Review
    Hindawi Gastroenterology Research and Practice Volume 2020, Article ID 2868373, 11 pages https://doi.org/10.1155/2020/2868373 Review Article S100A12 in Digestive Diseases and Health: A Scoping Review Alexandre Carvalho,1 Jacky Lu,2 Jamisha D. Francis,2 Rebecca E. Moore,3 Kathryn P. Haley,4 Ryan S. Doster,2,5 Steven D. Townsend,3 Jeremiah G. Johnson,6 Steven M. Damo,7,8,9 and Jennifer A. Gaddy 2,5,10 1Internal Medicine Program, St. Joseph Mercy Hospital, Ann Arbor, Michigan, USA 2Department of Pathology, Microbiology, And Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA 3Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA 4Department of Biomedical Sciences, Grand Valley State University, Allendale, Michigan, USA 5Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA 6Department of Microbiology, University of Tennessee, Knoxville, Tennessee, USA 7Department of Life and Physical Sciences, Fisk University, Nashville, Tennessee, USA 8Departments of Biochemistry and Chemistry, Vanderbilt University, Nashville, Tennessee, USA 9Department of Structural Biology, Vanderbilt University, Nashville, Tennessee, USA 10Tennessee Valley Healthcare Systems, Department of Veterans Affairs, Nashville, Tennessee, USA Correspondence should be addressed to Jennifer A. Gaddy; [email protected] Received 25 July 2019; Revised 5 January 2020; Accepted 22 January 2020; Published 26 February 2020 Academic Editor: Tatsuya Toyokawa Copyright © 2020 Alexandre Carvalho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Calgranulin proteins are an important class of molecules involved in innate immunity.
    [Show full text]
  • Urine S100 Proteins As Potential Biomarkers of Lupus Nephritis Activity
    Urine S100 Proteins as Potential Biomarkers of Lupus Nephritis Activity A thesis presented to the faculty of the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Master of Science in Clinical & Translational Research in the Department of Environmental Health of the College of Medicine by Jessica Turnier March 2017 B.S. & B.A. University of Pittsburgh, 2006 M.D. University of Cincinnati, 2011 Committee Chair: Erin Haynes, DrPH 1 Abstract Objective: Improved, non-invasive biomarkers are needed to accurately detect lupus nephritis (LN) activity. The purpose of this study was to evaluate five S100 proteins (S100A4, S100A6, S100A8/9 and S100A12) in both serum and urine as potential biomarkers of global and renal-specific disease activity in childhood-onset systemic lupus erythematosus (cSLE). Methods: In this multicenter study, S100 proteins were measured in the serum and urine of four cSLE cohorts and healthy controls using commercial ELISAs. Patients were divided into cohorts based on biospecimen availability: (1) longitudinal serum, (2) longitudinal urine, (3) cross-sectional serum, (4) cross-sectional urine. Global and renal disease activities were defined using the SLE disease activity index 2000 (SLEDAI-2K) and SLEDAI-2K renal domain score (SLEDAI-R). Results: All urine S100 proteins were elevated in active LN when compared to active extrarenal disease and healthy controls. All urinary S100 protein levels decreased with LN improvement, with S100A4 demonstrating the most significant decrease. Urine S100A4 levels were also higher with proliferative as compared to membranous LN. S100A4 staining in the kidney localized to mononuclear cells, podocytes and distal tubular epithelial cells.
    [Show full text]